Comorbiditeiten
Kohorst JJ, Kimball AB, Davis MDP. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol 2015;73:S27–35.
Obesitas
Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: A comprehensive review. J Am Acad Dermatol 2009;60:539–61.
Barth JH, Layton AM, Cunliffe WJ. Endocrine factors in pre and postmenopausal women with hidradenitis suppurativa. Br J Dermatol 1996;134:1057-9.
Canoui-Poitrine F, Revuz JE, Wolkenstein P et al. Clinical characteristics of a series of 302
French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009;61:51-7.
Crowley JJ, Mekkes JR, Zouboulis CC et al. Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities. Br J Dermatol 2014;171:1561–5. Gold DA, Reeder VJ, Mahan MG et al. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol 2014;70:699-703.
Kohorst JJ, Kimball AB, Davis MDP. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol 2015;73:S27–35.
Kromann CB, Deckers IE, Esmann S et al. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol 2014;171:819-24.
Miller IM, Ellervik C, Vinding GR et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 2014;150:1273–80.
Sartorius K, Emtestam L, Jemec GB et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009;161:831-9.
Schrader AM, Deckers IE, van der Zee HH et al. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol 2014;71:460-67.
Vazquez BG, Alikhan A, Weaver AL et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 2013;133:97-103.
Metaboolsyndroom
Crowley JJ, Mekkes JR, Zouboulis CC et al. Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities. Br J Dermatol 2014;171:1561-5. Gold DA, Reeder VJ, Mahan MG et al. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol 2014;70:699-703.
Kohorst JJ, Kimball AB, Davis MDP. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol 2015;73:S27–35.
Miller IM, Ellervik C, Vinding GR et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 2014;150:1273–80.
Revuz JE, Canoui-Poitrine F, Wolkenstein P et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008;59:596-601.
Sabat R, Chanwangpong A, Schneider-Burrus S et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One 2012;7:e31810.
Diabetes mellitus
Barth JH, Ng LL, Wojnarowska F et al. Acanthosis nigricans, insulin resistance and cutaneous virilism. Br J Dermatol 1988;118:613-19.
Gold DA, Reeder VJ, Mahan MG et al. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol 2014;70:699-703.
Miller IM, Ellervik C, Vinding GR et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 2014;150:1273–80.
O’Loughlin S, Woods R, Kirke PN et al. Hidradenitis suppurativa. Glucose tolerance, clinical, microbiologic, and immunologic features and HLA frequencies in 27 patients. Arch Dermatol 1988;124:1043-46.
Revuz JE, Canoui-Poitrine F, Wolkenstein P et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008;59: 596-601.
Sabat R, Chanwangpong A, Schneider-Burrus S et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One 2012;7:e31810.
Shlyankevich J, Chen AJ, Kim GE et al. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol 2014;71:1144-50.
Lipidenstoornissen
Gold DA, Reeder VJ, Mahan MG et al. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol 2014;70:699-703.
Kohorst JJ, Kimball AB, Davis MDP. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol 2015;73:S27–35.
Miller IM, Ellervik C, Vinding GR et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 2014;150:1273–80.
Sabat R, Chanwangpong A, Schneider-Burrus S et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One 2012;7:e31810.
Hormoongerelateerde stoornissen
Kromann CB, Deckers IE, Esmann S et al. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol 2014;171:819-24. Shlyankevich J, Chen AJ, Kim GE et al. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol 2014;71:1144-1150.
Roken
König A, Lehmann C, Rompel R et al. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999;198:261–4.
Kromann CB, Deckers IE, Esmann S et al. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol 2014;171:819–24.
Revuz JE, Canoui-Poitrine F, Wolkenstein P et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008;59: 596-601.
Sartorius K, Emtestam L, Jemec GB et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009;161:831–9. Schrader AM, Deckers IE, van der Zee HH et al. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol 2014;71:460–7.
Vazquez BG, Alikhan A, Weaver AL et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 2013;133:97–103.
Depressie
Crowley JJ, Mekkes JR, Zouboulis CC et al. Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities. Br J Dermatol 2014;171:1561–65. Sartorius K, Emtestam L, Jemec GB et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009;161:831–9.
Shavit E, Dreiher J, Freud T et al. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2015;29:371–6.
Vazquez BG, Alikhan A, Weaver AL et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 2013;133:97–103.
Inflammatoire darmziekte
Church JM, Fazio VW, Lavery IC et al. The differential diagnosis and comorbidity of hidradenitis suppurativa and perianal Crohn’s disease. Int J Colorectal Dis 1993;8:117–19. Dhaou BB, Boussema F, Aydi Z et al. Hidradenitis suppurativa (Verneuil’s disease). J Saudi Soc Dermatol Dermatol Surg 2013;17:1–5.
van der Zee HH, de Winter K, van der Woude CJ et al. The prevalence of hidradenitis suppurativa in 1093 patients with inflammatory bowel disease. Br J Dermatol 2014;171:673-5.
Yadav S, Singh S, Edakkanambeth Varayil J et al. Hidradenitis suppurativa in patients with inflammatory bowel disease: a population-based cohort study in Olmsted County, Minnesota. Clin Gastroenterol Hepatol 2016;14:65–70.
Artritis en spondylartropathie
Bhalla R, Sequeira W. Arthritis associated with hidradenitis suppurativa. Ann Rheum Dis 1994;53:64-6.
Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2010;2:9–16.
Richette P, Molto A, Viguier M et al. Hidradenitis suppurativa associated with spondyloarthritis—results from a multicenter national prospective study. J Rheumatol 2014;41:490-4.
Shlyankevich J, Chen AJ, Kim GE et al. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol 2014;71:1144-50.
Inflammatoire ziekte en begeleidende syndromen
Canoui-Poitrine F, Revuz JE, Wolkenstein P et al. Clinical characteristics of a series of 302
French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009;61:51–7.
Lim DT, James NM, Hassan S et al. Spondyloarthritis associated with acne conglobata, hidradenitis suppurativa and dissecting cellulitis of the scalp: a review with illustrative cases. Curr Rheumatol Rep 2013;15:346.
Maintz L, Betz RC, Allam JP et al. Keratitis-ichthyosis-deafness syndrome in association with follicular occlusion triad. Eur J Dermatol 2005;15:347–52.
Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009;23:985–98.
Thein M, Hogarth MB, Acland K. Seronegative arthritis associated with the follicular occlusion triad. Clin Exp Dermatol 2004;29:550–2.
Vazquez BG, Alikhan A, Weaver AL et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 2013;133:97–103.
Acne vulgaris
Canoui-Poitrine F, Revuz JE, Wolkenstein P et al. Clinical characteristics of a series of 302
French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009;61:51–57.
Schrader AM, Deckers IE, van der Zee HH et al. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol 2014;71:460–7.
Vazquez BG, Alikhan A, Weaver AL et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 2013;133:97–103.
Pyoderma gangrenosum
Ah-Weng A, Langtry JA, Velangi S et al. Pyoderma gangrenosum associated with hidradenitis suppurativa. Clin Exp Dermatol 2005;30:669–71.
Braun-Falco M, Kovnerystyy O, Lohse P et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)—a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 2012;66:409-15.
Duchatelet S, Miskinyte S, Join-Lambert O et al. First nicastrin mutation in PASH syndrome. Br J Dermatol 2015;173:610–12.
Hsiao JL, Antaya RJ, Berger T et al. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol 2010;146:1265–70. Reddick CL, Singh MN, Chalmers RJ. Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab. Dermatol Online J 2010;16:15.
Saraceno R, Babino G, Chiricozzi A et al. PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition. J Am Acad Dermatol 2015;72:e42–4.
Staub J, Pfannschmidt N, Strohal R et al. Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone. J Eur Acad Dermatol Venereol 2015a;29:2243–7.
Huidkanker
Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009;60:539–61.
Kohorst JJ, Kimball AB, Davis MDP. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol 2015;73:S27–35.
Lapins J, Ye W, Nyren O et al. Incidence of cancer among patients with hidradenitis suppurativa. Arch Dermatol 2001;137:730–4.
Maclean GM, Coleman DJ. Three fatal cases of squamous cell carcinoma arising in chronic perineal hidradenitis suppurativa. Ann R Coll Surg Engl 2007;89:709–12.
Shlyankevich J, Chen AJ, Kim GE et al. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol 2014;71:1144-150.
Vazquez BG, Alikhan A, Weaver AL et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 2013;133:97–103.